PARLIAMENTARY WRITTEN QUESTION
(11 February 2026)

To ask the Secretary of State for Health and Social Care, with reference to the Government response to the Women and Equalities Committee report on Tackling HIV transmission, HC 1663, what the basis is for the estimate that Cabotegravir injectable PrEP will impact 2,000 people; whether that figure is a cap on availability; and what steps his Department will take to ensure equitable access to injectable PrEP.

Asked by:
Sarah Owen (Labour)

Cabotegravir pre-exposure prophylaxis (PrEP) was recommended by the National Institute for Health and Care Excellence (NICE) as a clinically and cost-effective use for people who cannot have oral PrEP on 5 November 2025.

NICE estimated that up to 1,000 people would be eligible to receive cabotegravir injectable as PrEP but there is no cap on the number of people who may be eligible and therefore require and receive cabotegravir PrEP.

The new HIV Action Plan, published on 1 December 2025, sets out how the Government will enable every level of the healthcare system to work together to engage everyone in prevention, testing and treatment, tackling stigma, and reaching our ambition to end new HIV transmissions by 2030.

The Government will work with local authorities to expand alternative and digital delivery routes for injectable PrEP and audit current HIV technologies to identify gaps in provision. The UK Health Security Agency will publish local PrEP indicators to support action to reduce inequalities.

Answered by:
()